. Author manuscript; available in PMC: 2018 Sep 22.

Published in final edited form as: Obesity (Silver Spring). 2018 Mar 22;26(5):885–894. doi: 10.1002/oby.22166

Table 1.

Norepinephrine turnover (ng NE/g tissue/hr) in high-capacity runners (HCR) and low-capacity runners (LCR) 4 hrs after intra-ventromedial hypothalamic microinjection of either the mixed melanocortin receptor agonist MTII or vehicle. Mean±SEM

Tissue		HCR		LCR
Tissue		vehicle	MTII^*	vehicle	MTII^*
White adipose tissue	Mesenteric^†^**	18.88^** ± 2.30	38.73^** ± 4.72	8.39 ± 0.71	15.24 ± 1.30
	Retroperitoneal	8.04 ± 0.70	13.99 ± 1.23	6.32 ± 0.87	11.34 ± 1.56
	Epididymal^†^**	5.22^** ± 0.60	7.58^** ± 0.87	2.05 ± 0.11	5.56 ± 0.31
	Gluteal^†^**	4.92 ± 0.30	7.95^** ± 0.49	4.19 ± 0.37	4.52 ± 0.40
	Inguinal^†^**	2.29 ± 0.19	3.88^** ± 0.32	1.90 ± 0.17	2.43 ± 0.22
Brown adipose tissue^†^**		27.45^** ± 1.54	62.50^** ± 3.51	18.36 ± 1.06	30.91 ± 1.78
Liver^†		0.85 ± 0.10	2.11^** ± 0.26	0.66 ± 0.06	1.17 ± 0.10

HCR, high-capacity runners; LCR, low-capacity runners (N=7/HCR, 8/LCR)

MTII>vehicle, within line (HCR/LCR) when interaction was significant; all tissues showed main effect of MTII; p<0.05

^**

HCR≠LCR within treatment indicated; main effect of line (HCR/LCR) indicated on tissue; p<0.05

^†

Significant interaction between treatment (vehicle/MTII) and line (HCR/LCR); p<0.05